Capricor Shares Jump 8% After FDA Decision Timeline for Deramiocel Extended by 3 Months
CAPR Capricor Therapeutics Inc
$6.80 +8.11%
View chart & analysis → - 1Capricor Therapeutics (CAPR) shares rose 8% after the FDA extended the decision timeline for deramiocel by three months
- 2The deadline was pushed from August 22 to November 22, prompted by key supplemental BLA submissions including HOPE-3 24-month data
- 3H.C. Wainwright maintained a Neutral rating, noting that the risk of rejection remains high following the advisory committee's negative vote
This 3-line summary is compiled from the report below.
Bloomberg +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다